Previous studies have revealed that the activation of AKT/mTOR has a crucial effect on the progression of various cancers.16,18,25,42 At present, some anticancer drugs targeting (PI3K/AKT/mTOR) signaling pathways have been developed and progressed to various stages of clinical trials, and some have proven to be effective.43–45 Our findings provided a possible therapeutic target for the malignant progression of melanoma. Here, MTOR is linked to cancer.